Dr. Nathan on Long-Term Outcomes With Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
September 19th 2019
Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the long-term outcomes with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.